Pao Pereira extract suppresses benign prostatic hyperplasia by inhibiting inflammation-associated NFκB signaling.


Journal

BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232

Informations de publication

Date de publication:
16 May 2020
Historique:
received: 27 01 2020
accepted: 04 05 2020
entrez: 18 5 2020
pubmed: 18 5 2020
medline: 31 10 2020
Statut: epublish

Résumé

Our previous study revealed the extract from the bark of an Amazonian tree Pao Pereira can suppress benign prostatic hyperplasia (BPH) in a rat model. Herein, we examined its inhibitory effects on human BPH cells and dissect its molecular mechanism. We applied Pao extract to human BPH epithelial BPH-1 and prostate myofibroblast WPMY-1 cells. Cell viability, apoptosis and immunoblotting were performed, followed by gene expression profiling and gene set enrichment analysis (GSEA) to detect the differentially expressed genes and signaling pathway induced by Pao extract. Human ex vivo BPH explant organ culture was also used to examine the effects of Pao extract on human BPH tissues. Pao extract treatment inhibited viability and induced apoptosis in human BPH-1 and WPMY-1 cells. Gene expression profiling and the following validation indicated that the expression levels of pro-apoptotic genes (eg. PCDC4, CHOP and FBXO32) were induced by Pao extract in both two cell lines. GSEA further revealed that Pao extract treatment was negatively associated with the activation of NFκB signaling. Pao extract suppressed the transcriptional activity of NFκB and down-regulated its target genes involved in inflammation (CXCL5, CXCL6 and CXCL12) and extracellular matrix (ECM) remodeling (HAS2, TNC and MMP13) in both cultured cells and human ex vivo BPH explants. In both BPH epithelial and stromal cells, Pao extract induces apoptosis by upregulating the pro-apoptotic genes and inhibiting the inflammation-associated NFκB signaling via reducing phosphorylation of NFκB subunit RelA. Our data suggest that Pao extract may be a promising phytotherapeutic agent for BPH.

Sections du résumé

BACKGROUND BACKGROUND
Our previous study revealed the extract from the bark of an Amazonian tree Pao Pereira can suppress benign prostatic hyperplasia (BPH) in a rat model. Herein, we examined its inhibitory effects on human BPH cells and dissect its molecular mechanism.
METHODS METHODS
We applied Pao extract to human BPH epithelial BPH-1 and prostate myofibroblast WPMY-1 cells. Cell viability, apoptosis and immunoblotting were performed, followed by gene expression profiling and gene set enrichment analysis (GSEA) to detect the differentially expressed genes and signaling pathway induced by Pao extract. Human ex vivo BPH explant organ culture was also used to examine the effects of Pao extract on human BPH tissues.
RESULTS RESULTS
Pao extract treatment inhibited viability and induced apoptosis in human BPH-1 and WPMY-1 cells. Gene expression profiling and the following validation indicated that the expression levels of pro-apoptotic genes (eg. PCDC4, CHOP and FBXO32) were induced by Pao extract in both two cell lines. GSEA further revealed that Pao extract treatment was negatively associated with the activation of NFκB signaling. Pao extract suppressed the transcriptional activity of NFκB and down-regulated its target genes involved in inflammation (CXCL5, CXCL6 and CXCL12) and extracellular matrix (ECM) remodeling (HAS2, TNC and MMP13) in both cultured cells and human ex vivo BPH explants.
CONCLUSION CONCLUSIONS
In both BPH epithelial and stromal cells, Pao extract induces apoptosis by upregulating the pro-apoptotic genes and inhibiting the inflammation-associated NFκB signaling via reducing phosphorylation of NFκB subunit RelA. Our data suggest that Pao extract may be a promising phytotherapeutic agent for BPH.

Identifiants

pubmed: 32416730
doi: 10.1186/s12906-020-02943-2
pii: 10.1186/s12906-020-02943-2
pmc: PMC7231430
doi:

Substances chimiques

NF-kappa B 0
Plant Extracts 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

150

Subventions

Organisme : National Natural Science Foundation of China
ID : 81672873
Organisme : National Natural Science Foundation of China
ID : 81872373
Organisme : National Major Science and Technology Projects of China
ID : 2018ZX09711002
Organisme : Chinese Academy of Sciences
ID : One Hundred Talent Program
Organisme : Wu Jieping Medical Foundation
ID : 320.6750.16051
Organisme : Shanghai Songjiang Municipal Science and Technology Commission Natural Science Foundation
ID : 17SJKJGG10

Références

Lab Invest. 2012 Apr;92(4):615-24
pubmed: 22157716
Sci Rep. 2019 Dec 23;9(1):19703
pubmed: 31873149
Integr Cancer Ther. 2014 May;13(3):249-58
pubmed: 24287876
Oncol Rep. 2013 Jul;30(1):149-56
pubmed: 23674070
Rev Urol. 2004;6 Suppl 9:S3-S10
pubmed: 16985922
Prostate. 2009 Dec 1;69(16):1774-80
pubmed: 19670242
Nat Rev Dis Primers. 2016 May 05;2:16031
pubmed: 27147135
J Soc Integr Oncol. 2009 Spring;7(2):59-65
pubmed: 19476740
Integr Cancer Ther. 2018 Dec;17(4):1204-1215
pubmed: 29985062
Cancer Discov. 2012 Dec;2(12):1134-49
pubmed: 22993403
Dev Biol. 2008 Dec 15;324(2):310-9
pubmed: 18950615
In Vitro Cell Dev Biol Anim. 2015 Jan;51(1):50-8
pubmed: 25124870
Clin Cancer Res. 2012 Jul 1;18(13):3562-70
pubmed: 22573351
Sci Rep. 2019 Apr 15;9(1):6077
pubmed: 30988330
Oncogene. 2018 Jun;37(24):3317-3328
pubmed: 29559744
J Rheumatol. 2008 Jan;35(1):147-52
pubmed: 18061975
Lab Invest. 1992 Jan;66(1):96-107
pubmed: 1370561
Pharm Biol. 2014 Jan;52(1):36-43
pubmed: 24033267
Can J Urol. 2012 Oct;19 Suppl 1:10-7
pubmed: 23089343
J Biol Chem. 2010 Dec 3;285(49):38069-77
pubmed: 20923761
Sci Rep. 2016 Nov 16;6:37085
pubmed: 27848972
Prostate. 2016 Apr;76(5):491-511
pubmed: 26709083
Prostate. 2009 Apr 1;69(5):480-93
pubmed: 19107880
Urol Clin North Am. 2009 Nov;36(4):403-15, v
pubmed: 19942041
Carcinogenesis. 2014 Jul;35(7):1469-80
pubmed: 24413684
Immunogenetics. 2002 Nov;54(8):599-603
pubmed: 12439624
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Cytokine. 2008 Aug;43(2):194-9
pubmed: 18572414
Int J Oncol. 1995 Jul;7(1):81-5
pubmed: 21552810
Int J Oncol. 1994 Oct;5(4):873-9
pubmed: 21559655
Carcinogenesis. 2007 Feb;28(2):267-79
pubmed: 16840440

Auteurs

Yu Dong (Y)

Shanghai University, Shanghai, China.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China.

Jiakuan Liu (J)

Model Animal Research Center of Nanjing University, Nanjing, Jiangsu, China.

Zesheng Xue (Z)

Model Animal Research Center of Nanjing University, Nanjing, Jiangsu, China.

Jingya Sun (J)

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China.

Zhengnan Huang (Z)

Department of Urology, Shanghai General Hospital, Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, China.

Yifeng Jing (Y)

Department of Urology, Shanghai General Hospital, Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, China.

Bangmin Han (B)

Department of Urology, Shanghai General Hospital, Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, China.

Bing Shen (B)

Department of Urology, Shanghai General Hospital, Shanghai Jiaotong University, 100 Haining Road, Shanghai, 200080, China. shenbingyishi@163.com.

Jun Yan (J)

Department of Laboratory Animal Science, Fudan University, 130 Dong'an Road, Shanghai, 200032, China. yan_jun@fudan.edu.cn.
MOE Key Laboratory of Model Animals for Disease Study, Model Animal Research Center of Nanjing University, Nanjing, Jiangsu, China. yan_jun@fudan.edu.cn.

Ruimin Huang (R)

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai, 201203, China. rmhuang@simm.ac.cn.
University of Chinese Academy of Sciences, Beijing, 100049, China. rmhuang@simm.ac.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH